26 Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA. 51
Abnormal ocular motor control in Huntington`s disease. Neurology
1983; 33: 1268–75.
27 Carella F, Scaioli V, Ciano C, Binelli S, Oliva D, Girotti F. Adult 52
onset myoclonic Huntington's disease. Mov Disord 1993; 8: 201–05.
28 Jankovic J, Ashizawa T. Tourettism associated with Huntington's
disease. Mov Disord 1995; 10: 103–05. 53
29 Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C,
Chaudhuri KR. Late onset levodopa responsive Huntington's
disease with minimal chorea masquerading as Parkinson plus 54
syndrome. J Neurol Neurosurg Psychiatry 2000; 68: 238–41.
30 Tan EK, Jankovic J, Ondo W. Bruxism in Huntington's disease.
Mov Disord 2000; 15: 171–73. 55
31 Caine ED, Shoulson I. Psychiatric syndromes in Huntington's
disease. Am J Psychiatry 1983; 140: 728–33.
32 Mendez MF. Huntington's disease: update and review of
neuropsychiatric aspects. Int J Psychiatry Med 1994; 24: 189–208. 56
33 Schoenfeld M, Myers RH, Cupples LA, Berkman B, Sax DS,
Clark E. Increased rate of suicide among patients with
Huntington's disease. J Neurol Neurosurg Psychiatry 1984; 57
47: 1283–87.
34 Shiwach R. Psychopathology in Huntington's disease patients.
Acta Psychiatr Scand 1994; 90: 241–46. 58
35 Rosenblatt A, Leroi I. Neuropsychiatry of Huntington's disease and
other basal ganglia disorders. Psychosomatics 2000; 41: 24–30. 59
36 Rosenblatt A, Anderson K, Goumeniouk AD, et al. Clinical
management of aggression and frontal syndromes in Huntington's 60
disease. In: Bédard MA, Agid Y, Chouinard S, Fahn S, Korczyn AD,
Lesperance P, eds. Mental and behavioral dysfunction in 61
movement disorders. Totowa, New Jersey: Humana Press;
2003; 427–41. 62
37 Guttman M, Alpay M, Chouinard S, et al. Clinical management of
psychosis and mood disorders in Huntington's disease. In:
Bédard MA, Agid Y, Chouinard S, Fahn S, Korczyn AD, Lesperance 63
P, eds. Mental and behavioral dysfunction in movement disorders.
Totowa, New Jersey: Humana Press; 2003; 409–26.
38 Ho AK, Sahakian BJ, Brown RG, et al. Profile of cognitive 64
progression in early Huntington's disease. Neurology 2003;
61: 1702–06.
65
39 Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW,
Robbins TW. Executive and mnemonic functions in early
Huntington's disease. Brain 1996; 119: 1633–45.
66
40 Kirkwood SC, Su JL, Conneally P, Foroud T. Progression of
symptoms in the early and middle stages of Huntington disease.
Arch Neurol 2001; 58: 273–78.
67
41 Marshall F. Clinical features and treatment of Huntington's disease.
In: Watts RL, Koller WC, eds. Movement disorders: neurological
principles and practice, 2nd edn. McGraw-Hill; 2004; 589–601.
68
42 Sorensen SA, Fenger K. Causes of death in patients with
Huntington's disease and in unaffected first degree relatives.
J Med Genet 1992; 29: 911–14.
43 Lanska DJ, Lanska MJ, Lavine L, Schoenberg BS. Conditions 69
associated with Huntington's disease at death. A case-control study.
Arch Neurol 1988; 45: 878–80.
70
44 Bonelli RM, Wenning GK, Kapfhammer HP. Huntington's disease:
present treatments and future therapeutic modalities.
Int Clin Psychopharmacol 2004; 19: 51–62.
45 Huntington Study Group. Tetrabenazine as antichorea therapy in 71
Huntington disease: a randomized controlled trial. Neurology 2006;
66: 366–72.
72
46 Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a
randomized, controlled trial using the NMDA-antagonist
amantadine. Neurology 2002; 59: 694–99.
47 Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease 73
(HD): an open label study with one year follow up. J Neurol 2001;
248: 866–69.
48 Huntington Study Group. Dosage effects of riluzole in 74
Huntington's disease: a multicenter placebo-controlled study.
Neurology 2003; 61: 1551–56.
49 de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, 75
Specchio LM. Effects of rivastigmine on motor and cognitive
impairment in Huntington's disease. Mov Disord 2004; 19: 1516–18.
50 Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the 76
treatment of Huntington's disease. Eur J Neurol 2002; 9: 689–90.
